Metastatic Bone Disease Market Report 2026

Metastatic Bone Disease Market Overview

• Metastatic Bone Disease market size has reached to $18.82 billion in 2025 • Expected to grow to $28.84 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: Impact Of Bone Cancer Prevalence On The Metastatic Bone Disease Market • Market Trend: Biosimilar Therapies Expand Access And Improve Clinical Outcomes In Metastatic Bone Disease • North America was the largest region in 2025.

What Is Covered Under Metastatic Bone Disease Market?

Metastatic bone disease refers to the condition where cancer cells spread from their original (primary) site to the bones that weaken bones and cause symptoms such as pain, fractures, spinal cord compression, and hypercalcemia. Metastatic bone disease indicates that the cancer has progressed and is more difficult for treatment. The main treatments of metastatic bone disease include medication, radiation therapy, surgical intervention, and tumor ablation therapy. Medication refers to pharmaceutical drugs used to manage symptoms, slow disease progression, or treat underlying causes of bone metastases. They are originated from breast, lung, thyroid, kidney, prostate, and others. The various end-users include hospitals, specialty clinics, and ambulatory surgical centers.

What Is The Metastatic Bone Disease Market Growth Forecast?

The metastatic bone disease market size is expected to see strong growth in the next few years. It will grow to $28.84 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to growth in targeted bone agents, rising adoption of immunotherapy combinations, increasing demand for non-invasive tumor ablation, expansion of personalized treatment approaches, strengthening oncologic diagnostic capabilities. Major trends in the forecast period include advancements in targeted bone metastasis therapies, AI-assisted diagnostic imaging enhancement, digital platforms for remote symptom monitoring, automation in oncology radiology workflows, virtual reality-based surgical and treatment training.

Global Metastatic Bone Disease Market Segmentation

1) By Treatment: Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy 2) By Origin: Breast, Lung, Thyroid, Kidney, Prostate, Other Origins 3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers Subsegments: 1) By Medication: Bisphosphonates, Denosumab, Chemotherapy Drugs, Hormonal Therapies, Targeted Therapies, Radiation Therapy 2) By Radiation Therapy: External Beam Radiation Therapy, Internal Radiation Therapy 3) By Surgical Intervention: Bone Stabilization Surgery, Bone Resection Surgery, Spinal Decompression Surgery 4) By Tumor Ablation Therapy: Radiofrequency Ablation, Cryoablation, Microwave Ablation

What Is The Driver Of The Metastatic Bone Disease Market?

The increasing bone cancer is expected to propel the growth of the metastatic bone disease market going forward. Bone cancer refers to a malignant tumor that originates in the cells of the bone. The prevalence of bone cancer is driven by genetic factors, radiation exposure, and environmental factors such as exposure to certain chemicals. Bone cancer can lead to metastatic bone disease as cancer cells from the primary tumor spread through the bloodstream or lymphatic system, forming new tumors in other bones. For instance, in 2023, according to the American Cancer Society, a US-based non-profit organization, there were 3,970 new cases of bone and joint cancer reported, showing an increase compared to the 3,910 cases reported in 2022. Therefore, an increasing bone cancer prevalence is driving the growth of the metastatic bone disease industry.

Key Players In The Global Metastatic Bone Disease Market

Major companies operating in the metastatic bone disease market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Eli Lilly and Company, Amgen Inc., Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Jazz Pharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Mylan N.V., Novocure GmbH, Galapagos NV, Telix Pharmaceuticals Limited

Global Metastatic Bone Disease Market Trends and Insights

Major companies operating in the metastatic bone disease market are focusing on developing biosimilar therapies to improve patient access and reduce treatment costs while maintaining clinical efficacy. Biosimilars are biologic medical products highly similar to already approved reference medicines, with no clinically meaningful differences in safety or effectiveness. For instance, in March 2024, Sandoz, a Switzerland-based biopharmaceutical company, received FDA approval for Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), the first and only FDA-approved biosimilars of denosumab for all indications of the reference medicines. These include the prevention of skeletal-related events in patients with bone metastases from solid tumors. Such advancements are expected to enhance treatment accessibility and improve clinical outcomes for patients with metastatic bone disease.

What Are Latest Mergers And Acquisitions In The Metastatic Bone Disease Market?

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired QSAM Biosciences for an undisclosed amount. The acquisition aims to bolster Telix's therapeutic pipeline, strengthening its position in radiopharmaceutical innovation and widening its focus on oncology and rare diseases. Through this deal, Telix intends to accelerate the development and delivery of treatments for bone metastases, aiming to provide significant benefits to affected patients. QSAM Biosciences Inc. is a US-based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

Regional Outlook

North America was the largest region in the metastatic bone disease market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Metastatic Bone Disease Market?

The metastatic bone disease market consists of revenues earned by entities by providing services such as chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic bone disease market includes sales of intramedullary rods, plates and screws, prosthetic devices, spinal instrumentation, and radiation therapy accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Metastatic Bone Disease Market Report 2026?

The metastatic bone disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic bone disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.